Entering text into the input field will update the search result below

Merck's late-stage KEYNOTE-355 trial met endpoint of overall survival in breast cancer study

  • Merck (NYSE:MRK) announces positive results from the Phase 3 KEYNOTE-355 trial evaluating Keytruda, in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC).
  • Findings from the final analysis show first-line treatment with Keytruda in combination

Recommended For You

More Trending News

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.